Transgene: TG4050: Individualized Cancer Vaccine in HPV-Negative Head & Neck Cancers
About The Event
Join us for a virtual KOL event with Transgene, featuring expert medical oncologist Christian Ottensmeier, MD, PhD, FRCP (University of Liverpool, La Jolla Institute for Immunology) who will discuss the unmet medical need and current treatment landscape for patients suffering from head and neck cancers.
Following Dr. Ottensmeier’s presentation, Transgene’s Management team will provide a company update, highlighting new Phase I data, recently presented at AACR in April, confirming the high immunogenicity and promising efficacy profile of TG4050, an individualized neoantigen cancer vaccine developed by Transgene in collaboration with NEC Corporation.
A live Q&A session will follow the formal presentations.